कंपनी का अवलोकन
EUDA Health Holdings Limited is a specialized entity engaged in the provision of non-invasive healthcare services, operating primarily across Singapore, Malaysia, and China. The company's business model encompasses the delivery of bioenergy capsules, stem cell therapy, CRISPR gene editing treatments, and supplements, alongside property management services. It operates within the Real Estate sector, specifically classified under the Real Estate Services industry, which typically involves asset management, leasing, and related service provision. The company demonstrates a market capitalization of $13.48M and reports annual revenue of $5.16M with an operational workforce of 117 employees. These financial metrics indicate that EUDA Health Holdings Limited functions as a small-cap entity with a relatively modest revenue base compared to large-scale real estate developers or major healthcare conglomerates. The disparity between its healthcare service offerings and its classification in the Real Estate sector suggests a diversified operational structure where property management may play a significant role in its revenue generation alongside medical services.
वित्तीय स्वास्थ्य
The company reported a total revenue of $5.16M over the trailing twelve months, yet it recorded a net income of -$2,064,341 and an EBITDA of -$1,992,526, highlighting a significant structural cost burden relative to its sales volume. The substantial gap between positive revenue and negative net income reveals that operating expenses, including the costs associated with medical therapies and property management, exceed the gross profit generated by its services. Free cash flow stands at -$3,350,164, indicating that the company is burning cash to fund its operations and growth initiatives, which limits its immediate financial flexibility for internal expansion or debt repayment without external capital injection. Margins further illustrate this financial pressure: a gross margin of 22.4% suggests moderate efficiency in direct service delivery, while an operating margin of -37.0% and a profit margin of 5.2% reflect high overhead costs and the impact of non-operating expenses on the bottom line. The balance sheet shows cash holdings of $176,584 against total debt of $2.28M, and with a debt-to-equity ratio listed as N/A due to negative equity implications, the company relies on leverage that poses liquidity risks. Liquidity is critically constrained by a current ratio of 0.23, signaling that current assets are less than a quarter of current liabilities, which creates potential challenges in meeting short-term obligations. Return on Equity is N/A and return on assets stands at -63.9%, metrics that collectively indicate that management has not yet generated positive returns on capital deployed and that asset utilization is currently detracting from shareholder value.
मूल्यांकन आकलन
Valuation metrics present a complex picture with a trailing P/E ratio of 17.83 contrasted sharply against a forward P/E of 4.46, implying that the market anticipates a dramatic turnaround in earnings or a significant restructuring of the company's profitability trajectory. The price-to-book ratio is recorded at -3.57, a negative figure that suggests the company's market value is substantially below its book value, often seen in distressed assets or firms with significant accumulated losses. Alternative valuation measures such as the price-to-sales ratio of 2.61 and an EV/EBITDA of -7.70 provide context independent of earnings, suggesting the market prices the stock based on revenue multiples rather than profitability given the negative EBITDA. The stock trades within a wide range, with a 52-week high of $86.00 and a 52-week low of $6.42, placing the current trading price significantly below the recent peak and reflecting high market sentiment volatility. The beta value of 0.16 indicates that the stock's price volatility is substantially lower than the broader market, suggesting that EUDA Health Holdings Limited behaves as a defensive or low-correlation asset despite its financial distress.
Growth & Income
Revenue growth year-over-year has accelerated at 60.2%, demonstrating a rapid expansion in top-line sales, while earnings growth is N/A due to the company's persistent net losses, implying that revenue expansion has not yet translated into profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, instead reinvesting its limited liquidity and capital to sustain operations and fund its growth initiatives. The combination of high revenue growth and negative earnings growth suggests that the company is in an early-stage or turnaround phase where market share acquisition takes precedence over immediate profit generation. The overall growth and income profile is characterized by aggressive revenue expansion funded by cash burn, with no current income distribution mechanism for investors relying on yield.